Evidence map›Paper›PMID 38349448›Full record

ArticleVirus genes2024

Characterization of a breakthrough vaccine escape strain associated with overt hepatitis B virus infection.

Mohammed El-Mowafy, Mohamed Elegezy, Mohamed El-Mesery, Abdelaziz Elgaml

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virus genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohammed El-MowafyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Mohamed ElegezyDepartment of Endemic Hepatology and Gastroenterology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed El-MeseryDepartment of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Abdelaziz ElgamlDepartment of Microbiology and Immunology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. elgamel3a@mans.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) vaccine is composed of the purified hepatitis B surface antigen (HBsAg) that is produced by recombinant DNA technology. The neutralizing antibodies induced by vaccination target mainly the "a" determinant, aa124-147, of the outer viral envelope (HBsAg). In the present work, we demonstrate a case study for vaccinated patient that is infected with a vaccine escape HBV strain (Eg200). Characterization of the isolate Eg200 showed that it belongs to the genotype D and an uncommon sub-genotype in Egypt; D9. The DNA sequence encoding HBsAg was sequenced. Mutational analysis of the HBsAg showed a double mutation in the "a" determinant of this HBV isolate; T125M and P127T. However, such substitutions were found to be conserved to the detected serotype, ayw3, of Eg200 isolate. This case report indicates that continuous characterization of breakthrough vaccine escape strains of HBV is essential to develop the immunization strategies against HBV infection.

Indexed as

Hepatitis BHepatitis B virusDNA, ViralHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesHumansMutationDNA, ViralHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesHepatitis B surface antigenHepatitis B virusMutational analysisVaccine escape

Identifiers

PMID38349448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.